of the Supplement The parent project was proposed to investigate the role of the activation of SRF in aortic stiffening, however, the mechanisms underlying the increase of SRF in hypertensive VSMCs remains unknown. The work performed on the parent grant directly led to the identification of interleukin 36 receptor (IL-36R), an inflammatory regulator, which was dramatically increased in the hypertensive aortic tissue and VSMCs, and established a potential link of the IL-36R with SRF activation in hypertensive VSMCs. These new findings built the foundation of the present supplemental application. One of the goals of this supplement is to expand the research of the parent grant to explore the potential role of IL-36R in the development of aortic stiffening in hypertension and its association with SRF-mediated signaling. Another goal of this supplement is to support the candidate?s investigation in this new research area extended from the parent grant, and help her to become an R01-funded principal investigator in 1-2 years. Based on our preliminary data, we hypothesize that the upregulation of IL-36R contributes to aortic stiffness in hypertension by increasing VSMC stiffness through SRF-mediated signaling. We plan to test this hypothesis by pursuing the following specific aims:
Aim 1 : Determine the role of IL-36R in VSMC stiffness and its regulation on SRF?mediated signaling in vitro. We will use a gain- and loss-of-function strategy to identify IL-36R-dependent effects at the cell level. We will test whether overexpressing IL-36R in WKY VSMCs increases the VSMC stiffness, and whether knocking- down IL-36R results in a reversal of the enhanced stiffness of SHR VSMCs. In addition, we will use IL-36R agonists and antagonists to determine whether the effect of IL-36R requires activation by an IL-36 cytokine. The VSMCs stiffness will be measured by AFM and 3D constituted tissue models as we proposed in the parent grant. We will also determine whether overexpressing or knocking down IL-36R in VSMCs induces a parallel alteration on the SRF-mediated signaling by testing the key genes and proteins as demonstrated in the parent grant.
Specific Aim 2 : Determine the role of IL-36R in the development of aortic stiffening and hypertension in vivo. To accomplish this, we will determine whether IL-36R is necessary for the regulation of aortic stiffness by using a VSMC-specific IL-36R KO mouse model. We will test whether the deletion of IL-36R affects the aortic stiffening and blood pressure induced by Angiotensin II in these mice. The aortic stiffness will be measured both in vivo and ex vivo as we described in the parent proposal. The VSMC stiffness and involved signaling will be determined in the isolated TA VSMCs from these mice as proposed in the Aim1. We expect that this supplement will discover novel mechanisms that may link the IL-36R with SRF-mediated intracellular signaling which will lead to a better understanding in the pathogenesis of aortic stiffness in hypertension and to help the candidate ?s career development.
Hypertension is a common vascular disorder and is a major risk factor for cardiovascular complications. The research proposed in this application is relevant to public health because it is expected to enhance our understanding of how the inflammatory actions of IL-36R impact the pathological processes of aortic stiffness and hypertension. This new knowledge could lead to novel avenues of research for hypertension treatment and lay the foundation for future discoveries in cardiovascular disorders that effect the function of blood vessels.
Showing the most recent 10 out of 14 publications
